基于伏邪理论探讨低氧性肺动脉高压肺血管重塑
Pulmonary Vascular Remodeling in Hypoxic Pulmonary Hypertension Based on the Theory of Hypoxia
DOI: 10.12677/TCM.2023.128326, PDF,    科研立项经费支持
作者: 李 娟:湖北中医药大学第一临床学院,湖北 武汉;尹 琴:湖北中医药大学附属新华医院呼吸与危重症医学科(湖北省中西医结合医院呼吸与危重症医学科), 湖北 武汉
关键词: 伏邪低氧性肺动脉高压肺血管重塑Latent Evil Hypoxic Pulmonary Hypertension Pulmonary Vascular Remodeling
摘要: 低氧性肺动脉高压(Hypoxic Pulmonary Hypertension, HPH)是一种由缺氧引起的极其复杂的心肺疾病,其病理机制极其复杂,其中,肺血管不可逆性重塑是HPH的显著病理特征之一,在HPH的发生发展中发挥着重要作用,因此尽早干预肺血管重塑是防治HPH及其并发症的关键所在。本文以伏邪为研究基础,认为伏邪藏匿于体内的过程与肺血管重塑有相似之处。脏腑功能失调是伏邪产生的基础,痰浊、瘀血是伏邪的关键组成部分,肺之络脉是伏邪的主要藏匿部位,而肺络受损则是伏邪致病的结果。本文将从中医学伏邪相关理论对肺血管重塑进行阐述,以期为HPH的治疗提供新的思路。
Abstract: Hypoxic pulmonary hypertension is an extremely complex cardiopulmonary disease caused by hypoxia, and its pathological mechanism is extremely complex. Irreversible remodeling of pulmonary vessels is one of the significant pathological features of HPH, and plays an important role in the occurrence and development of HPH. Therefore, early intervention in pulmonary vascular remodeling is the key to prevention and treatment of HPH and its complications. Based on the study of latent disease, this paper believes that the process of latent disease hiding in the body is similar to pulmonary vascular remodeling. The dysfunction of the zang-fu organs is the basis of the emergence of latent evil, the phlegm turbidness and blood stasis are the key components of latent evil, the lung complex is the main hiding place of latent evil, and the lung collateral damage is the result of latent evil. In order to provide new ideas for the treatment of HPH, this paper will expound pulmonary vascular remodeling based on the theory of pathogenic pathogens in TCM.
文章引用:李娟, 尹琴. 基于伏邪理论探讨低氧性肺动脉高压肺血管重塑[J]. 中医学, 2023, 12(8): 2174-2179. https://doi.org/10.12677/TCM.2023.128326

参考文献

[1] 中国肺动脉高压诊断与治疗指南(2021版) [J]. 中华医学杂志, 2021, 101(1): 11-51.
[2] 王岚, 易群. 《中国肺动脉高压诊断与治疗指南(2021版)》解读——肺部疾病和(或)低氧所致肺动脉高压[J]. 中国实用内科杂志, 2022, 42(1): 55-59. [Google Scholar] [CrossRef
[3] Rosenkranz, S., Howard, L.S., Gomberg-Maitland, M. and Hoeper, M.M. (2020) Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. Circulation, 141, 678-693. [Google Scholar] [CrossRef
[4] 马菁苑, 蔡雨春, 姚冬. 肺动脉高压中的肺血管重塑[J]. 医学研究生学报, 2021, 34(9): 985-990. [Google Scholar] [CrossRef
[5] 王建美, 袁天翊, 高丽, 秦雪梅, 杜冠华. 低氧性肺动脉高压病理机制与治疗药物研究进展[J]. 中国药理学通报, 2022, 38(9): 1281-1288.
[6] 刘燕, 吴耀松, 刘俊, 张文娴, 陈玉龙. 内生伏邪实质及致病特点探析[J]. 上海中医药杂志, 2022, 56(2): 27-29. [Google Scholar] [CrossRef
[7] 梁艳霞, 代昭欣, 樊茂蓉, 王冰, 李广森, 赵晓利, 王书臣. 王书臣运用伏邪理论辨治肺结节经验[J]. 中医杂志, 2022, 63(15): 1416-1419. [Google Scholar] [CrossRef
[8] 张泰, 张北华, 马祥雪, 王凤云, 尹晓岚, 陈婷, 唐旭东. 从伏邪学说辨析幽门螺杆菌阳性慢性萎缩性胃炎炎-癌转化病机[J]. 中华中医药杂志, 2022, 37(6): 3132-3136.
[9] 张攀, 周秀娟, 李文翰, 崔修平, 钱俊辉, 罗才贵. 基于伏邪理论探讨慢性阻塞性肺疾病气道重塑[J]. 中华中医药杂志, 2020, 35(12): 6206-6208.
[10] Humbert, M., Guignabert, C., Bonnet, S., et al. (2019) Pathology and Pathobiology of Pulmonary Hypertension: State of the Art and Research Perspectives. European Respiratory Journal, 53, Article ID: 1801887. [Google Scholar] [CrossRef] [PubMed]
[11] 王蕊, 王志萍. 低氧性肺动脉高压的肺血管重建机制研究进展[J]. 国际麻醉学与复苏杂志, 2020, 41(3): 301-304.
[12] Kammerer, T., Faihs, V., Hulde, N., et al. (2020) Hypoxic-Inflammatory Responses under Acute Hypoxia: In Vitro Experiments and Prospective Observational Expedition Trial. International Journal of Molecular Sciences, 21, Article No. 1034. [Google Scholar] [CrossRef] [PubMed]
[13] Poch, D. and Mandel, J. (2021) Pulmonary Hypertension. Annals of Internal Medicine, 174, C49-C64. [Google Scholar] [CrossRef
[14] 廖艺璇, 陈亚红, 米文君. 慢性阻塞性肺疾病肺血管重塑的研究进展[J]. 生理科学进展, 2016, 47(4): 295-299.
[15] 曲畅, 吴云红, 穆靖洲, 朱亮. 核转录因子-κB在缺氧导致的炎症中的作用[J]. 生理科学进展, 2018, 49(1): 39-43.
[16] Zhang, T., Zhu, X., Wu, H., et al. (2019) Targeting the ROS/PI3K/AKT/HIF-1α/HK2 Axis of Breast Cancer Cells: Combined Administration of Polydatin and 2-Deoxy-D-Glucose. Journal of Cellular and Molecular Medicine, 23, 3711-3723. [Google Scholar] [CrossRef] [PubMed]
[17] 郭畅, 丁超伟, 袁雅冬. 低氧性肺动脉高压中缺氧诱导因子1α调节机制的研究进展[J]. 实用心脑肺血管病杂志, 2023, 31(7): 27-32..
[18] 蔡静, 侯丽辉. 痰浊与现代物质基础的关系[J]. 辽宁中医杂志, 2007(6): 742-743. [Google Scholar] [CrossRef
[19] 潘桂娟. 论中医学之“痰”的形成及特性[J]. 中华中医药杂志, 2009, 24(6): 765-767.
[20] 贾连群, 杨关林. 动脉粥样硬化中医痰浊血瘀证候的现代生物学基础研究[J]. 中西医结合心脑血管病杂志, 2010, 8(1): 95-96.
[21] 程建超, 李泽庚, 张星星, 童佳兵, 杨勤军, 倪萍. 益气化痰祛瘀法对慢性阻塞性肺疾病气道重构及血管内皮生长因子影响的研究[J]. 中医药临床杂志, 2018, 30(6): 987-990. [Google Scholar] [CrossRef
[22] 常艳宾, 张丽丽, 李雁. 从痰浊血瘀理论探讨冠心病的发病机制[J]. 现代中西医结合杂志, 2022, 31(3): 368-371.
[23] 刘勇明, 吕晓东, 庞立健, 刘创, 刘妍彤. 基于肺络构效理论的肺脏生理功能发微[J]. 中华中医药学刊, 2017, 35(10): 2518-2520. [Google Scholar] [CrossRef
[24] 张浩洋, 庞立健, 刘创, 徐嘉, 吕晓东. 慢性复杂性肺疾病的共性病机及治疗策略[J]. 上海中医药杂志, 2018, 52(4): 12-14. [Google Scholar] [CrossRef
[25] 黄菲菲, 李耀浙, 张婷, 王良兴, 黄晓颖. 红景天苷通过抑制氧化应激防治大鼠低氧性肺动脉高压[J]. 中国病理生理杂志, 2018, 34(3): 500-506.